Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood. 2013;122(23):3723-3734.

On page 3725 in the 28 November 2013 issue, there is a typographical error. The first line (the sentence begins on page 3724) reads, “Similar results were obtained in a trial comparing FCR without FC in relapsed CLL without demonstrating a benefit for OS.⁴⁰” The sentence should have read, “Similar results were obtained in a trial comparing FCR with FC in relapsed CLL without demonstrating a benefit for OS.⁴⁰”

⁴⁰Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756-1765.